Global Chronic Obstructive Pulmonary Disorder (COPD) Market Research Report 2023

Report ID: 1900852 | Published Date: Sep 2024 | No. of Page: 89 | Base Year: 2023 | Rating: 4 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
        1.2.2 Short-Acting Bronchodilators
        1.2.3 Corticosteroids
        1.2.4 Methylxanthines
        1.2.5 Long-Acting Bronchodilators
        1.2.6 Phosphodiesterase-4 Inhibitors
        1.2.7 Others
    1.3 Market by Application
        1.3.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Application: 2017 VS 2021 VS 2028
        1.3.2 Hospital
        1.3.3 Clinic
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Perspective (2017-2028)
    2.2 Chronic Obstructive Pulmonary Disorder (COPD) Growth Trends by Region
        2.2.1 Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Chronic Obstructive Pulmonary Disorder (COPD) Historic Market Size by Region (2017-2022)
        2.2.3 Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Region (2023-2028)
    2.3 Chronic Obstructive Pulmonary Disorder (COPD) Market Dynamics
        2.3.1 Chronic Obstructive Pulmonary Disorder (COPD) Industry Trends
        2.3.2 Chronic Obstructive Pulmonary Disorder (COPD) Market Drivers
        2.3.3 Chronic Obstructive Pulmonary Disorder (COPD) Market Challenges
        2.3.4 Chronic Obstructive Pulmonary Disorder (COPD) Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Revenue
        3.1.1 Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Revenue (2017-2022)
        3.1.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Players (2017-2022)
    3.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Chronic Obstructive Pulmonary Disorder (COPD) Revenue
    3.4 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Concentration Ratio
        3.4.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Chronic Obstructive Pulmonary Disorder (COPD) Revenue in 2021
    3.5 Chronic Obstructive Pulmonary Disorder (COPD) Key Players Head office and Area Served
    3.6 Key Players Chronic Obstructive Pulmonary Disorder (COPD) Product Solution and Service
    3.7 Date of Enter into Chronic Obstructive Pulmonary Disorder (COPD) Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Obstructive Pulmonary Disorder (COPD) Breakdown Data by Type
    4.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Historic Market Size by Type (2017-2022)
    4.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Type (2023-2028)
5 Chronic Obstructive Pulmonary Disorder (COPD) Breakdown Data by Application
    5.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Historic Market Size by Application (2017-2022)
    5.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2017-2028)
    6.2 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2017-2022)
    6.3 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2023-2028)
    6.4 United States
    6.5 Canada
7 Europe
    7.1 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2017-2028)
    7.2 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2017-2022)
    7.3 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2023-2028)
    7.4 Germany
    7.5 France
    7.6 U.K.
    7.7 Italy
    7.8 Russia
    7.9 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2017-2028)
    8.2 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2017-2022)
    8.3 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2023-2028)
    8.4 China
    8.5 Japan
    8.6 South Korea
    8.7 Southeast Asia
    8.8 India
    8.9 Australia
9 Latin America
    9.1 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2017-2028)
    9.2 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2017-2022)
    9.3 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2023-2028)
    9.4 Mexico
    9.5 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2017-2028)
    10.2 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2017-2022)
    10.3 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2023-2028)
    10.4 Turkey
    10.5 Saudi Arabia
    10.6 UAE
11 Key Players Profiles
    11.1 GSK
        11.1.1 GSK Company Detail
        11.1.2 GSK Business Overview
        11.1.3 GSK Chronic Obstructive Pulmonary Disorder (COPD) Introduction
        11.1.4 GSK Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
        11.1.5 GSK Recent Development
    11.2 Pfizer
        11.2.1 Pfizer Company Detail
        11.2.2 Pfizer Business Overview
        11.2.3 Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Introduction
        11.2.4 Pfizer Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
        11.2.5 Pfizer Recent Development
    11.3 Merck
        11.3.1 Merck Company Detail
        11.3.2 Merck Business Overview
        11.3.3 Merck Chronic Obstructive Pulmonary Disorder (COPD) Introduction
        11.3.4 Merck Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
        11.3.5 Merck Recent Development
    11.4 Novartis
        11.4.1 Novartis Company Detail
        11.4.2 Novartis Business Overview
        11.4.3 Novartis Chronic Obstructive Pulmonary Disorder (COPD) Introduction
        11.4.4 Novartis Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
        11.4.5 Novartis Recent Development
    11.5 AstraZeneca
        11.5.1 AstraZeneca Company Detail
        11.5.2 AstraZeneca Business Overview
        11.5.3 AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Introduction
        11.5.4 AstraZeneca Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
        11.5.5 AstraZeneca Recent Development
    11.6 Boehringer Ingelheim
        11.6.1 Boehringer Ingelheim Company Detail
        11.6.2 Boehringer Ingelheim Business Overview
        11.6.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Introduction
        11.6.4 Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
        11.6.5 Boehringer Ingelheim Recent Development
    11.7 Teva Pharmaceuticals
        11.7.1 Teva Pharmaceuticals Company Detail
        11.7.2 Teva Pharmaceuticals Business Overview
        11.7.3 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Introduction
        11.7.4 Teva Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
        11.7.5 Teva Pharmaceuticals Recent Development
    11.8 Ario Pharma
        11.8.1 Ario Pharma Company Detail
        11.8.2 Ario Pharma Business Overview
        11.8.3 Ario Pharma Chronic Obstructive Pulmonary Disorder (COPD) Introduction
        11.8.4 Ario Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
        11.8.5 Ario Pharma Recent Development
    11.9 Roche
        11.9.1 Roche Company Detail
        11.9.2 Roche Business Overview
        11.9.3 Roche Chronic Obstructive Pulmonary Disorder (COPD) Introduction
        11.9.4 Roche Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
        11.9.5 Roche Recent Development
    11.10 Ache
        11.10.1 Ache Company Detail
        11.10.2 Ache Business Overview
        11.10.3 Ache Chronic Obstructive Pulmonary Disorder (COPD) Introduction
        11.10.4 Ache Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
        11.10.5 Ache Recent Development
    11.11 Almirall
        11.11.1 Almirall Company Detail
        11.11.2 Almirall Business Overview
        11.11.3 Almirall Chronic Obstructive Pulmonary Disorder (COPD) Introduction
        11.11.4 Almirall Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
        11.11.5 Almirall Recent Development
    11.12 Aquinox Pharmaceuticals
        11.12.1 Aquinox Pharmaceuticals Company Detail
        11.12.2 Aquinox Pharmaceuticals Business Overview
        11.12.3 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Introduction
        11.12.4 Aquinox Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
        11.12.5 Aquinox Pharmaceuticals Recent Development
    11.13 Asmacure
        11.13.1 Asmacure Company Detail
        11.13.2 Asmacure Business Overview
        11.13.3 Asmacure Chronic Obstructive Pulmonary Disorder (COPD) Introduction
        11.13.4 Asmacure Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
        11.13.5 Asmacure Recent Development
    11.14 Astellas Pharma
        11.14.1 Astellas Pharma Company Detail
        11.14.2 Astellas Pharma Business Overview
        11.14.3 Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD) Introduction
        11.14.4 Astellas Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
        11.14.5 Astellas Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Tables
    Table 1. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
    Table 2. Key Players of Short-Acting Bronchodilators
    Table 3. Key Players of Corticosteroids
    Table 4. Key Players of Methylxanthines
    Table 5. Key Players of Long-Acting Bronchodilators
    Table 6. Key Players of Phosphodiesterase-4 Inhibitors
    Table 7. Key Players of Others
    Table 8. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
    Table 9. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 10. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2017-2022) & (US$ Million)
    Table 11. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Region (2017-2022)
    Table 12. Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 13. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Region (2023-2028)
    Table 14. Chronic Obstructive Pulmonary Disorder (COPD) Market Trends
    Table 15. Chronic Obstructive Pulmonary Disorder (COPD) Market Drivers
    Table 16. Chronic Obstructive Pulmonary Disorder (COPD) Market Challenges
    Table 17. Chronic Obstructive Pulmonary Disorder (COPD) Market Restraints
    Table 18. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Players (2017-2022) & (US$ Million)
    Table 19. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Players (2017-2022)
    Table 20. Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Obstructive Pulmonary Disorder (COPD) as of 2021)
    Table 21. Ranking of Global Top Chronic Obstructive Pulmonary Disorder (COPD) Companies by Revenue (US$ Million) in 2021
    Table 22. Global 5 Largest Players Market Share by Chronic Obstructive Pulmonary Disorder (COPD) Revenue (CR5 and HHI) & (2017-2022)
    Table 23. Key Players Headquarters and Area Served
    Table 24. Key Players Chronic Obstructive Pulmonary Disorder (COPD) Product Solution and Service
    Table 25. Date of Enter into Chronic Obstructive Pulmonary Disorder (COPD) Market
    Table 26. Mergers & Acquisitions, Expansion Plans
    Table 27. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2017-2022) & (US$ Million)
    Table 28. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Type (2017-2022)
    Table 29. Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 30. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Type (2023-2028)
    Table 31. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2017-2022) & (US$ Million)
    Table 32. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Application (2017-2022)
    Table 33. Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 34. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Application (2023-2028)
    Table 35. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2017-2022) & (US$ Million)
    Table 36. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2023-2028) & (US$ Million)
    Table 37. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2017-2022) & (US$ Million)
    Table 38. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2023-2028) & (US$ Million)
    Table 39. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2017-2022) & (US$ Million)
    Table 40. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2023-2028) & (US$ Million)
    Table 41. Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2017-2022) & (US$ Million)
    Table 42. Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2023-2028) & (US$ Million)
    Table 43. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2017-2022) & (US$ Million)
    Table 44. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2023-2028) & (US$ Million)
    Table 45. GSK Company Detail
    Table 46. GSK Business Overview
    Table 47. GSK Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 48. GSK Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million)
    Table 49. GSK Recent Development
    Table 50. Pfizer Company Detail
    Table 51. Pfizer Business Overview
    Table 52. Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 53. Pfizer Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million)
    Table 54. Pfizer Recent Development
    Table 55. Merck Company Detail
    Table 56. Merck Business Overview
    Table 57. Merck Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 58. Merck Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million)
    Table 59. Merck Recent Development
    Table 60. Novartis Company Detail
    Table 61. Novartis Business Overview
    Table 62. Novartis Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 63. Novartis Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million)
    Table 64. Novartis Recent Development
    Table 65. AstraZeneca Company Detail
    Table 66. AstraZeneca Business Overview
    Table 67. AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 68. AstraZeneca Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million)
    Table 69. AstraZeneca Recent Development
    Table 70. Boehringer Ingelheim Company Detail
    Table 71. Boehringer Ingelheim Business Overview
    Table 72. Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 73. Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million)
    Table 74. Boehringer Ingelheim Recent Development
    Table 75. Teva Pharmaceuticals Company Detail
    Table 76. Teva Pharmaceuticals Business Overview
    Table 77. Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 78. Teva Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million)
    Table 79. Teva Pharmaceuticals Recent Development
    Table 80. Ario Pharma Company Detail
    Table 81. Ario Pharma Business Overview
    Table 82. Ario Pharma Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 83. Ario Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million)
    Table 84. Ario Pharma Recent Development
    Table 85. Roche Company Detail
    Table 86. Roche Business Overview
    Table 87. Roche Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 88. Roche Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million)
    Table 89. Roche Recent Development
    Table 90. Ache Company Detail
    Table 91. Ache Business Overview
    Table 92. Ache Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 93. Ache Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million)
    Table 94. Ache Recent Development
    Table 95. Almirall Company Detail
    Table 96. Almirall Business Overview
    Table 97. Almirall Chronic Obstructive Pulmonary Disorder (COPD)Product
    Table 98. Almirall Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million)
    Table 99. Almirall Recent Development
    Table 100. Aquinox Pharmaceuticals Company Detail
    Table 101. Aquinox Pharmaceuticals Business Overview
    Table 102. Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD)Product
    Table 103. Aquinox Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million)
    Table 104. Aquinox Pharmaceuticals Recent Development
    Table 105. Asmacure Company Detail
    Table 106. Asmacure Business Overview
    Table 107. Asmacure Chronic Obstructive Pulmonary Disorder (COPD)Product
    Table 108. Asmacure Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million)
    Table 109. Asmacure Recent Development
    Table 110. Astellas Pharma Company Detail
    Table 111. Astellas Pharma Business Overview
    Table 112. Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD)Product
    Table 113. Astellas Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million)
    Table 114. Astellas Pharma Recent Development
    Table 115. Research Programs/Design for This Report
    Table 116. Key Data Information from Secondary Sources
    Table 117. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Type: 2021 VS 2028
    Figure 2. Short-Acting Bronchodilators Features
    Figure 3. Corticosteroids Features
    Figure 4. Methylxanthines Features
    Figure 5. Long-Acting Bronchodilators Features
    Figure 6. Phosphodiesterase-4 Inhibitors Features
    Figure 7. Others Features
    Figure 8. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Application in 2021 & 2028
    Figure 9. Hospital Case Studies
    Figure 10. Clinic Case Studies
    Figure 11. Chronic Obstructive Pulmonary Disorder (COPD) Report Years Considered
    Figure 12. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 13. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 14. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Region: 2021 VS 2028
    Figure 15. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Players in 2021
    Figure 16. Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Obstructive Pulmonary Disorder (COPD) as of 2021)
    Figure 17. The Top 10 and 5 Players Market Share by Chronic Obstructive Pulmonary Disorder (COPD) Revenue in 2021
    Figure 18. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 19. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Country (2017-2028)
    Figure 20. United States Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 21. Canada Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 22. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Country (2017-2028)
    Figure 24. Germany Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 25. France Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. U.K. Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. Italy Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. Russia Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. Nordic Countries Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Region (2017-2028)
    Figure 32. China Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Japan Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. South Korea Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. Southeast Asia Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. India Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. Australia Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Country (2017-2028)
    Figure 40. Mexico Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Brazil Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Country (2017-2028)
    Figure 44. Turkey Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 45. Saudi Arabia Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 46. GSK Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
    Figure 47. Pfizer Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
    Figure 48. Merck Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
    Figure 49. Novartis Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
    Figure 50. AstraZeneca Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
    Figure 51. Boehringer Ingelheim Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
    Figure 52. Teva Pharmaceuticals Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
    Figure 53. Ario Pharma Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
    Figure 54. Roche Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
    Figure 55. Ache Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
    Figure 56. Almirall Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
    Figure 57. Aquinox Pharmaceuticals Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
    Figure 58. Asmacure Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
    Figure 59. Astellas Pharma Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022)
    Figure 60. Bottom-up and Top-down Approaches for This Report
    Figure 61. Data Triangulation
    Figure 62. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
GSK
Pfizer
Merck
Novartis
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceuticals
Ario Pharma
Roche
Ache
Almirall
Aquinox Pharmaceuticals
Asmacure
Astellas Pharma
Frequently Asked Questions
Chronic Obstructive Pulmonary Disorder (COPD) report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Chronic Obstructive Pulmonary Disorder (COPD) report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Chronic Obstructive Pulmonary Disorder (COPD) report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports